SynopsisSemagacestat is an inhibitor of the γ-secretase complex. It causes a reduction in the secretion of Aβ42, Aβ40 and Aβ38 from H4 human glioma cells stably overexpressing human wild-type APP into the culture medium. The global Semagacestat market was valued.....
SynopsisPurvalanol A is a cell-permeable, potent, and selective inhibitor of cyclin-dependent kinases. The global Purvalanol A (CDK Inhibitor) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during.....
SynopsisIndoprofen(CAS 31842-01-0) is a non-steroidal drug, which can show a range of pharmacological properties such as analgesic and anti-inflammatory activities. The global Indoprofen market was valued at US$ million in 2023 and is anticipated to reach US$ mi.....
SynopsisPeficitinib(CAS 944118-01-8) is a novel potent JAK inhibitor, which demonstrated potent efficacy in adjuvant-induced arthritis model in rats. The global Peficitinib market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030,.....
SynopsisBaricitinib (CAS 1187594-09-7) is an orally bioavailable inhibitor of Janus kinases 1 and 2, with potential anti-inflammatory, immunomodulating and antineoplastic activities. The global Baricitinib market was valued at US$ million in 2023 and is anticipa.....
SynopsisValrubicin (CAS 56124-62-0) is a semisynthetic derivative of the antineoplastic anthracycline antibiotic doxorubicin. The global Valrubicin market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % d.....
SynopsisPreladenant (CAS 377727-87-2) is a potent and selective antagonist at the adenosine A2A receptor. The global Preladenant market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast .....
SynopsisMonomethyl Fumarate (CAS 2756-87-8), the active metabolite of the psoriasis drug Fumaderm, is a potent GPR109A agonist. The global Monomethyl Fumarate market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a .....
SynopsisAcebilustat (CAS 943764-99-6), also known as ZK322, is a novel, oral, potent and selective leukotriene A4 hydrolase inhibitor that is a promising new once-daily oral antiinflammatory drug in development for treatment of cystic fibrosis (CF) and other diseases......
SynopsisDithranol (CAS 1143-38-0) is a hepsin activity inhibitor used for treatment of psoriasis. Dithranol exerts a direct effect on keratinocytes and leukocytes. The global Dithranol market was valued at US$ million in 2023 and is anticipated to reach US$ mill.....
